查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1564006

小動物影像（體內）的全球市場

Small Animal Imaging (In-Vivo)
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球小動物影像（體內）市場將達到 48 億美元

全球小動物影像（體內）市場預計 2023 年為 29 億美元，預計到 2030 年將達到 48 億美元，2023-2030 年分析期間複合年成長率為 7.7%。微磁共振成像是本報告分析的細分市場之一，預計複合年成長率為 8.9%，到分析期結束時將達到 11 億美元。分析期間光學成像領域的複合年成長率預計為 7.2%。

美國市場預估為7.937億美元，中國預期複合年成長率為7.0%

預計 2023 年美國小動物影像（體內）市場規模將達 7.937 億美元。中國作為世界第二大經濟體，預計到 2030 年市場規模將達到 7.352 億美元，2023-2030 年分析期間複合年成長率為 7.0%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 7.3% 和 6.2%。在歐洲，德國的複合年成長率預計約為 6.1%。

全球小動物影像（體內）市場－主要趨勢與促進因素總結

為什麼小動物影像對於臨床前研究至關重要？

小動物影像（體內）對於臨床前研究至關重要，因為它為監測活體動物的生物過程提供了非侵入性高解析度成像解決方案。此技術廣泛應用於藥物開發、癌症研究、循環系統研究和神經科學，以評估疾病進展、治療效果和藥物動力學。磁振造影（MRI）、正子斷層掃描（PET）、單光子發射電腦斷層掃描（SPECT）、電腦斷層掃描（CT）等小型動物成像技術提供即時、縱向、定量的資料，增強可信度和臨床前研究的轉化價值。對個人化醫療、標靶治療和分子影像的日益關注正在推動小動物影像系統在研究機構、製藥公司和學術實驗室中的採用。

科技進步如何增強小動物影像？

技術進步正在透過整合多模態、混合、人工智慧驅動的成像系統來增強小動物成像，從而提供對生物過程的全面洞察。結合 MRI、PET、SPECT 和 CT 的多模態影像系統的研究和開發使研究人員能夠同時獲得多個資料點，從而提高臨床前研究的準確性和深度。基於人工智慧的影像分析、深度學習演算法和資料管理系統的創新正在促進影像資料的自動化、高通量和定量分析，減少臨床前工作流程的時間和複雜性。此外，可攜式、緊湊且易於使用的成像系統的出現擴大了中小型實驗室對先進成像技術的使用範圍，增強了協作研究和知識共用。

小動物影像的主要市場區隔是什麼？

影像方式包括微型 MRI、PET、SPECT、CT、光學成像（生物發光和螢光）和超音波，其中光學成像和 PET 因其高靈敏度、特異性和即時成像能力而引領市場。使用案例包括腫瘤學、神經學、循環系統、感染疾病學和免疫學，其中腫瘤學因其活躍的癌症研究和藥物開發研究而成為最大的領域。最終用戶包括學術和研究機構、製藥和生物技術公司以及CRO（委外研發機構）。從地理上看，北美和歐洲因其先進的研究基礎設施而成為小動物成像的最大市場，而亞太地區則看到生命科學投資的增加、研發活動的擴大以及對精準醫學的關注。下的成長區域。

推動小動物影像市場成長的因素有哪些？

小動物成像市場的成長受到多種因素的推動，包括臨床前研究和藥物開發的需求不斷增加，多模態、混合和人工智慧主導的成像系統的日益採用，以及非侵入性高解析度成像技術的進步會被帶來。緊湊、便攜且易於使用的成像系統的市場開拓正在推動學術研究機構、製藥公司和 CRO 的市場採用。對高靈敏度、高特異性和即時成像模式的需求不斷成長，導致各種臨床前研究應用的市場擴張。小動物影像在腫瘤學、神經學、循環系統和免疫學研究中的使用越來越多，加上對縱向、定量和平移成像解決方案的需求，正在為市場成長創造新的機會。此外，研究機構、製藥公司和影像解決方案供應商之間加強合作以及增加對創新成像技術研發的投資正在進一步推動市場擴張。

受訪企業範例（42家知名企業）

  • Aspect Imaging Ltd.
  • Berthold Technologies GmbH & Co. KG
  • Bruker Corp.
  • LI-COR Biosciences, Inc.
  • Mediso Ltd.
  • MILabs BV
  • Miltenyi Biotec GmbH
  • New England Biolabs, Inc.
  • Northridge Tri-Modality Imaging, Inc.
  • PerkinElmer, Inc.
  • Scanco Medical AG
  • Sofie Biosciences, Inc.
  • Thermo Fisher Scientific Inc.
  • Uvp. LLC

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP14774

Global Small Animal Imaging (In-Vivo) Market to Reach US$4.8 Billion by 2030

The global market for Small Animal Imaging (In-Vivo) estimated at US$2.9 Billion in the year 2023, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2023-2030. Micro-Magnetic Resonance Imaging, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Optical Imaging segment is estimated at 7.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$793.7 Million While China is Forecast to Grow at 7.0% CAGR

The Small Animal Imaging (In-Vivo) market in the U.S. is estimated at US$793.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$735.2 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.3% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Small Animal Imaging (In-Vivo) Market - Key Trends and Drivers Summarized

Why Is Small Animal Imaging Essential for Preclinical Studies?

Small animal imaging (in-vivo) is crucial for preclinical studies as it provides non-invasive, high-resolution imaging solutions for monitoring biological processes in live animals. This technology is extensively used in drug development, cancer research, cardiovascular studies, and neuroscience to assess disease progression, therapeutic efficacy, and pharmacokinetics. Small animal imaging techniques, such as Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Computed Tomography (CT), offer real-time, longitudinal, and quantitative data, enhancing the reliability and translational value of preclinical research. The increasing focus on personalized medicine, targeted therapies, and molecular imaging is driving the adoption of small animal imaging systems across research institutions, pharmaceutical companies, and academic laboratories.

How Are Technological Advancements Enhancing Small Animal Imaging?

Technological advancements are enhancing small animal imaging by integrating multi-modal, hybrid, and AI-driven imaging systems that provide comprehensive insights into biological processes. The development of multi-modal imaging systems combining MRI, PET, SPECT, and CT modalities is enabling researchers to capture multiple data points simultaneously, improving the accuracy and depth of preclinical studies. Innovations in AI-based image analysis, deep learning algorithms, and data management systems are facilitating automated, high-throughput, and quantitative analysis of imaging data, reducing the time and complexity of preclinical workflows. Furthermore, the emergence of portable, compact, and user-friendly imaging systems is expanding the accessibility of advanced imaging technologies to small and mid-sized research labs, enhancing collaboration and knowledge sharing.

Which Market Segments Are Leading the Adoption of Small Animal Imaging?

Imaging modalities include micro-MRI, PET, SPECT, CT, optical imaging (bioluminescence and fluorescence), and ultrasound, with optical imaging and PET leading the market due to their high sensitivity, specificity, and real-time imaging capabilities. Use case encompass oncology, neurology, cardiology, infectious diseases, and immunology, with oncology being the largest segment due to the high prevalence of cancer research and drug development studies. End-users include academic and research institutions, pharmaceutical and biotechnology companies, and contract research organizations (CROs), with academic and research institutions being the primary adopters due to their focus on basic research and translational studies. Geographically, North America and Europe are the largest markets for small animal imaging due to advanced research infrastructure, while Asia-Pacific is emerging as a high-growth region driven by increasing investments in life sciences, expanding R&D activities, and growing focus on precision medicine.

What Are the Key Drivers of Growth in the Small Animal Imaging Market?

The growth in the small animal imaging market is driven by several factors, including the rising demand for preclinical research and drug development, increasing adoption of multi-modal, hybrid, and AI-driven imaging systems, and advancements in non-invasive, high-resolution imaging technologies. The development of compact, portable, and user-friendly imaging systems is driving market adoption among academic and research institutions, pharmaceutical companies, and CROs. The growing demand for high-sensitivity, high-specificity, and real-time imaging modalities is expanding the market reach among diverse preclinical research applications. The increasing use of small animal imaging in oncology, neurology, cardiology, and immunology research, coupled with the demand for longitudinal, quantitative, and translational imaging solutions, is creating new opportunities for market growth. Additionally, the rising collaborations between research institutes, pharmaceutical companies, and imaging solution providers and the increasing investments in R&D for innovative imaging technologies are further supporting market expansion.

Select Competitors (Total 42 Featured) -

  • Aspect Imaging Ltd.
  • Berthold Technologies GmbH & Co. KG
  • Bruker Corp.
  • LI-COR Biosciences, Inc.
  • Mediso Ltd.
  • MILabs B.V.
  • Miltenyi Biotec GmbH
  • New England Biolabs, Inc.
  • Northridge Tri-Modality Imaging, Inc.
  • PerkinElmer, Inc.
  • Scanco Medical AG
  • Sofie Biosciences, Inc.
  • Thermo Fisher Scientific Inc.
  • Uvp. LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Small Animal Imaging (In-Vivo) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Non-Invasive, High-Resolution Imaging Technologies Propel Market Innovation
    • Increasing Focus on Personalized Medicine and Molecular Imaging Expands Addressable Market Opportunity
    • Integration of Multi-Modal Imaging Systems (MRI, PET, SPECT, CT) Reinforces Market Competitiveness
    • Rising Investments in Oncology, Neurology, and Cardiovascular Research Spurs Market Adoption
    • Focus on Enhancing Imaging Sensitivity, Specificity, and Quantitative Analysis Drives Market Demand
    • Emergence of AI-Driven Image Analysis and Deep Learning Algorithms in Small Animal Imaging Accelerates Market Transformation
    • Growing Use of Fluorescence, Bioluminescence, and Ultrasound Imaging in In-Vivo Studies Sustains Market Growth
    • Development of Compact, User-Friendly, and High-Throughput Imaging Systems Expands Market Reach
    • Rising Preference for Longitudinal, Real-Time, and 4D Imaging Modalities Generates New Growth Opportunities
    • Growing Application of Small Animal Imaging in Infectious Diseases, Immunology, and Regenerative Medicine Spurs Market Expansion
    • Shift Towards Hybrid Imaging Platforms, Portable Solutions, and Remote Data Analysis Supports Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Small Animal Imaging (In-Vivo) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Small Animal Imaging (In-Vivo) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Small Animal Imaging (In-Vivo) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Micro-magnetic resonance imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Micro-magnetic resonance imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Micro-magnetic resonance imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Optical imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Optical imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Optical imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Nuclear imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Nuclear imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Nuclear imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Imaging Modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Imaging Modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Imaging Modalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Monitoring treatment response by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Monitoring treatment response by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Monitoring treatment response by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Bio-distribution of drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Bio-distribution of drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Bio-distribution of drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cancer cell detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cancer cell detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cancer cell detection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Longitudinal studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Longitudinal studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Longitudinal studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Epigenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Epigenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Epigenetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Small Animal Imaging (In-Vivo) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Small Animal Imaging (In-Vivo) by Imaging Modality - Percentage Breakdown of Value Sales for Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Small Animal Imaging (In-Vivo) by Application - Percentage Breakdown of Value Sales for Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Small Animal Imaging (In-Vivo) by Imaging Modality - Percentage Breakdown of Value Sales for Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Small Animal Imaging (In-Vivo) by Application - Percentage Breakdown of Value Sales for Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics for the Years 2014, 2024 & 2030
  • JAPAN
    • Small Animal Imaging (In-Vivo) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Small Animal Imaging (In-Vivo) by Imaging Modality - Percentage Breakdown of Value Sales for Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Small Animal Imaging (In-Vivo) by Application - Percentage Breakdown of Value Sales for Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics for the Years 2014, 2024 & 2030
  • CHINA
    • Small Animal Imaging (In-Vivo) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Small Animal Imaging (In-Vivo) by Imaging Modality - Percentage Breakdown of Value Sales for Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Small Animal Imaging (In-Vivo) by Application - Percentage Breakdown of Value Sales for Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics for the Years 2014, 2024 & 2030
  • EUROPE
    • Small Animal Imaging (In-Vivo) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Small Animal Imaging (In-Vivo) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Small Animal Imaging (In-Vivo) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Small Animal Imaging (In-Vivo) by Imaging Modality - Percentage Breakdown of Value Sales for Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Small Animal Imaging (In-Vivo) by Application - Percentage Breakdown of Value Sales for Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics for the Years 2014, 2024 & 2030
  • FRANCE
    • Small Animal Imaging (In-Vivo) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Small Animal Imaging (In-Vivo) by Imaging Modality - Percentage Breakdown of Value Sales for Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities for the Years 2014, 2024 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Small Animal Imaging (In-Vivo) by Application - Percentage Breakdown of Value Sales for Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics for the Years 2014, 2024 & 2030
  • GERMANY
    • Small Animal Imaging (In-Vivo) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Small Animal Imaging (In-Vivo) by Imaging Modality - Percentage Breakdown of Value Sales for Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities for the Years 2014, 2024 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Small Animal Imaging (In-Vivo) by Application - Percentage Breakdown of Value Sales for Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Small Animal Imaging (In-Vivo) by Imaging Modality - Percentage Breakdown of Value Sales for Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities for the Years 2014, 2024 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Small Animal Imaging (In-Vivo) by Application - Percentage Breakdown of Value Sales for Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Small Animal Imaging (In-Vivo) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Small Animal Imaging (In-Vivo) by Imaging Modality - Percentage Breakdown of Value Sales for Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities for the Years 2014, 2024 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Small Animal Imaging (In-Vivo) by Application - Percentage Breakdown of Value Sales for Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Small Animal Imaging (In-Vivo) by Imaging Modality - Percentage Breakdown of Value Sales for Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Small Animal Imaging (In-Vivo) by Application - Percentage Breakdown of Value Sales for Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Small Animal Imaging (In-Vivo) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Small Animal Imaging (In-Vivo) by Imaging Modality - Percentage Breakdown of Value Sales for Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Small Animal Imaging (In-Vivo) by Application - Percentage Breakdown of Value Sales for Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for Small Animal Imaging (In-Vivo) by Imaging Modality - Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of World 16-Year Perspective for Small Animal Imaging (In-Vivo) by Imaging Modality - Percentage Breakdown of Value Sales for Micro-magnetic resonance imaging, Optical imaging, Nuclear imaging and Other Imaging Modalities for the Years 2014, 2024 & 2030
    • TABLE 107: Rest of World Recent Past, Current & Future Analysis for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of World Historic Review for Small Animal Imaging (In-Vivo) by Application - Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of World 16-Year Perspective for Small Animal Imaging (In-Vivo) by Application - Percentage Breakdown of Value Sales for Monitoring treatment response, Bio-distribution of drug, Cancer cell detection, Biomarkers, Longitudinal studies and Epigenetics for the Years 2014, 2024 & 2030

IV. COMPETITION